Single-dose self-amplifying COVID-19 vaccine (iDMV-1.0)
Evaluation of iDMV-1.0: A Single Dose Self-Amplifying Vaccine for SARS-CoV-2
['FUNDING_OTHER'] · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · NIH-11163500
Tests whether a single-shot self‑amplifying vaccine called iDMV‑1.0 can produce strong protection against COVID‑19 with a controlled immune response.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE (nih funded) |
| Locations | 1 site (BURLINGTON, UNITED STATES) |
| Trial ID | NIH-11163500 on ClinicalTrials.gov |
What this research studies
This project aims to develop a single‑shot, self‑amplifying COVID‑19 vaccine designed to produce strong immunity after one dose. Researchers are studying lipid nanoparticles (LNPs), the delivery particles used in many vaccines, to understand how their physical features shape immune reactions. In the lab they use CRISPR‑Cas9 screens in immune cells to find the genes and pathways that make some LNPs more or less inflammatory and they study which stromal cells sense and pass along those signals. The goal is to use those findings to design LNPs that give the right level of immune activation with fewer side effects.
Who could benefit from this research
Good fit: Ideal participants would be adults at risk of COVID‑19 or volunteers willing to donate blood or join early‑phase vaccine or sample‑collection efforts, likely local to the study site.
Not a fit: People seeking immediate access to an already approved COVID‑19 vaccine or those unable to enroll in vaccine research due to medical exclusions may not receive direct benefit.
Why it matters
Potential benefit: If successful, this work could enable a single‑dose COVID‑19 vaccine that provides strong protection with fewer adverse reactions.
How similar studies have performed: LNP delivery has underpinned the highly successful mRNA COVID‑19 vaccines, but single‑dose self‑amplifying platforms and CRISPR‑based mapping of LNP immune effects are newer and less proven.
Where this research is happening
BURLINGTON, UNITED STATES
- UNIVERSITY OF VERMONT & ST AGRIC COLLEGE — BURLINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAJUMDAR, DEVDOOT — UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
- Study coordinator: MAJUMDAR, DEVDOOT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.